MELAS syndrome
Not recruitingLong-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial
Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial
- Disease:MELAS syndrome
- Substances:Zagociguat
Italy- Participants:18–64 years · 65+ years
- Substances:Zagociguat
- Sponsor:Tisento Therapeutics Inc.









